Revolutionizing Healthcare: Asclepath Secures ¥30 Million in Pre-Seed Funding to Launch Zero-Admin AI Clinics

Funding Overview

Asclepath Inc. has announced the successful closure of a ¥30 million pre-seed funding round led by Garnet Capital, coinciding with the company's official incorporation on July 10, 2026. The startup aims to pioneer a new operational paradigm in healthcare: the "AI-native clinic."

About Asclepath Inc.

Founded by CEO and practicing physician Dr. Shota Hamada, Asclepath is a healthcare startup built on the core philosophy that "doctors should focus on patients while AI manages the clinic." Based in Shinjuku, Tokyo, the company is driving medical digital transformation (DX) through the development of its proprietary AI Operating System (AIOS).

Purpose of Funding and Future Outlook

The newly acquired capital will be allocated toward the following strategic initiatives:

• Accelerating the development of the "Asclepath AIOS" aimed at eliminating the need for administrative staff.
• Expanding Proof of Concept (PoC) efforts for the AI-native clinic model.
• Scaling medical DX operations and consulting services for healthcare providers.
• Strengthening support services for new medical practice openings.
• Building out sales and deployment infrastructure.

By centralizing functions such as scheduling, reception, patient intake, electronic medical record (EMR) documentation, billing, marketing, and business analytics, Asclepath aims to create an environment where physicians can dedicate themselves entirely to patient care.

List of Investors

• Garnet Capital (General Partner: Kyosuke Seto)